Answers are grounded in this paper and cite their sources.
The initial aim in developing a substitute for blood was driven by the perception that the blood supply was not safe and not sufficient. This no longer appears to be critical, and the present goal is that of obtaining an alternative that is better than blood. The task is not simple because while most blood-transported gases are effective in small amounts, oxygen is required in quantities not accommodated by its solubility in plasma. Contenders as oxygen transporters are hemoglobin (Hb), fluorocarbons and increased plasma gas solubility by high oxygen concentration ventilation. Of these Hb remains unsurpassed in its ability to transport large quantities of oxygen at physiological partial pressures. Hemoglobin is one of the potent biochemicals in the organism that in normal conditions are carefully isolated from the surroundings. It carries oxygen via a reversible reaction with iron which oxidizes and reduces at room temperature as a function of the local oxygen pressure (pO2), while the atomic element does this at 2,000°C. The ability to bridge these widely different levels of energy suggests a latent hazard that can arise once hemoglobin leaves its environmental niche devised by evolution, within the red blood cell (RBC). This issue of Transfusion Alternatives in Transfusion Medicine describes the state of the development of blood substitutes, analyzing its biochemical basis and the biological consequences of using Hb as an oxygen carrier in the microcirculation. A common trend of the contributions is that Hb use as an oxygen carrier ultimately results is an exercise in taming its powerful latent biochemical potential. This, however, also leads to the possibility of deriving physiological benefit not solely related to oxygen-carrying capacity. Buehler and Alayash1 illustrate the events taking place once Hb is liberated from the protective environment of RBCs where it is shielded from oxidative processes by enzymatic and small molecule antioxidants. In the absence of the RBC membrane, Hb is prone to oxidize and interact directly with other cells, proteins and lipids, causing cytotoxicity via a process of cellular lipid peroxidation. In this condition the remaining protection is provided by the antioxidative status of plasma and tissue. Ascorbic acid (AA) and uric acid become critical for maintaining hemoglobin-based oxygen carriers (HBOCs) in a reduced and functional state. Not all species generate the same levels of AA, and many results are obtained in species like rats that produce large amounts of endogenous AA, particularly when they become stressed. Notably humans are a non-AA producing species, a fact that may explain some indications of cell damage resulting from using HBOCs. This concept originates primarily from in vitro findings, raising the question of whether they occur in vivo. However, since other forms of Hb-based toxicity are being neutralized, these mechanisms remain a potential toxicity that, if operational, must be counteracted. Vandegriff et al.2 describe an HBOC based on polyethylene glycol (PEG) modified molecular Hb, challenging the notion of inherent toxicity of this type of compounds with the demonstration that Hb can be chemically modified to avoid problematic side effects, particularly vasoconstriction and the promotion of oxidation in vivo. The modifications obtained yield a counterintuitive set of characteristics that include (i) increased Hb molecular size to prolong intravascular retention; (ii) increased oxygen affinity to prevent premature unloading of oxygen in the arterioles and arteriolar vasoconstriction; and (iii) increased colloidal osmotic pressure and viscosity to enhance microvascular blood flow. Following the general scheme of protecting the environment from the molecule, in this case protection should be in part provided by the ∼5 Å layer of water that PEG immobilizes near the Hb surface. Complete isolation of the Hb from the circulation is attained by the encapsulation of Hb in phospholipid liposome vesicles (HbV). This approach described by Sakai et al.3 is the result of a major research effort promoted by the Ministry of Health, Labor and Welfare of Japan. Encapsulation allows controlling the oxidative conditions in the environment of the Hb, and provides a means for setting oxygen-carrying capacity and oxygen saturation properties. These HbVs are provided with a PEG coating on their surface, which minimizes their interaction with blood-formed elements. Being large particles with diameters of the order of 200 nm, they exert no osmotic effects and, like RBCs, they carry a significant amount of Hb. Their colligative properties (i.e. viscosity and colloid osmotic pressure) are determined by the formulation of the fluid in which they are delivered. Novel Hb confinement systems that mimic the immuno-isolative properties of the RBC membrane for use as a HBOC that prevents both dissociation of Hb and in vivo exposure of acellular Hb are presented by Harris and Palmer.4 These cellular types of Hb constructs comprise vesicles with an inner polymerized scaffolding that provides structural support to the membrane and an ellipsoidal shape in solution. PEG vesicles can also be produced using amphiphilic diblock copolymers instead of natural lipids, resulting in polymer vesicles called polymersomes, which have comparatively large intravascular persistence. Nanoscale hydrogel based particles are a novel Hb confinement system for use as a HBOC. These particles1 dimensions can be made to change as a function of changes in temperature and pH, a property of potential use in directing the particles to specific tissue and organs. Blood performs its functions by providing oxygen-carrying capacity and plasma expansion. This combination is asymmetrical, since the circulation has excess oxygen-carrying capacity while its plasma-expansion capacity is limited. This distribution of properties suggests that blood substitutes may maintain the functionality of the circulating blood by sacrificing oxygen-carrying capacity if plasma expansion can be provided for. This approach is in principle realizable if ‘improved plasma expansion’ is definable, and the factors that determine this condition are known. The article by Tsai et al.5 addresses this issue, showing that maintenance of perfusion is the priority in resuscitation and that there may be an advantage with the gradual restoration of oxygen-carrying capacity. Attainment of this goal results from restituting viscosity of blood rather than its oxygen-carrying capacity after a major blood loss, a process that results in improved flow and capillary perfusion. On this basis, Acharya et al.6 deploy new chemical platforms for Hb pegylation aimed at endowing the Hb molecule with the viscogenic, osmostic and oxygen transport properties that optimize oxygen delivery in the presence of improved perfusion, without necessarily restituting intrinsic oxygen-carrying capacity to normal levels. This strategy is also aimed at reducing the quantity of molecular Hb to be introduced in the circulation, thus minimizing costs as well as the potential hazards voiced by Buehler ad Alayash.1 Viscosity is proposed to play a key new role in significantly increasing the efficiency of plasma expansion. However, Lenz et al.7 analyze the effects of changing blood viscosity in the brain and propose that whole-blood viscosity is a negligible factor as a determinant of microvascular perfusion under physiological conditions when autoregulation is effective. They support this assertion by noting the normality of microvascular perfusion in a species that overproduces RBCs by genetic manipulation, though this species is adapted to elevate blood viscosity since birth. They conclude that in the brain, under pathological conditions, increases of overall viscosity should be avoided, however this cannot be generalized to all organ systems since Martini et al.8 show that increasing blood viscosity by 10% increases cardiac output and lowers blood pressure and peripheral vascular resistance. It should be noted that Tsai et al.5 do not advocate that increasing blood viscosity is beneficial. The key issue is to restore blood viscosity when it is decreased by hemodilution, an effect achieved by increasing plasma viscosity while maintaining overall blood viscosity below systemic values, thus obtaining a beneficial increase in capillary pressure that leads to increased capillary perfusion, concomitantly decreasing peripheral vascular resistance. Blood is transfused when the circulating Hb concentration reaches about 7 g/dL. At this Hb concentration, all blood-related transport properties fall to about half the normal value, particularly blood viscosity. However, 50% hemodilution does not correspond to a significant fall in either blood pressure or cardiac output if normovolemia is maintained. This is due to hemodilution eliciting vasoconstriction due to the combination of baroreceptor reflexes and the decrease of shears stress on the vascular wall, which lowers nitric oxide (NO) increasing peripheral vascular resistance. It is increasingly recognized that blood transports several gases beyond oxygen and carbon dioxide (CO2). Another critical gas is nitric oxide (NO), given its ability to regulate blood flow and mediate inflammation. It was recently shown that the reactions between NO and Hb are also dependent on the oxy- or deoxy- condition of Hb, which leads to the possibility of establishing a regulatory mechanism where the quantity of NO produced is proportional to the degree of hypoxia and, therefore, is directly related to the oxygen supply and demand of the tissue. This mechanism, discussed by Lancaster et al.,9 could be of major importance because molecular HBOCs place Hb in much closer proximity to the endothelium than RBCs. These authors also discuss the reactions between the anion nitrite and deoxyhemoglobin resulting in NO formation, a mechanism termed nitrite-reductase reactivity of Hb. This process could be an important pathway for NO signaling that provides the possibility of using nitrite as an adjunct therapy to HBOCs. Cabrales and Friedman10 analyze in detail the problem of vasoactivity due to molecular Hb and the regulation of blood flow in hypoxia, and conclude that there is no presently proposed mechanism that fully explains the lack of vasoactivity of PEG-Hb. This is evident considering that the increased plasma viscosity shown to restore and improve microvascular perfusion is not operational with PEG-Hb (or PEG-albumin, PEG-Alb) since its high oncotic pressure precludes using concentrations that cancel vasoactivity via increased viscosity. Furthermore, PEG-Hb scavenges NO in the same manner as Hb formulations that are vasoactive. The finding that PEG-Hb and PEG-Alb have similar properties suggests that negative vasoactivity is related to the pegylation process. Free NO needs to be bound to a carrier molecule to form a stable and ‘bioactive’ form of NO which can be transported to and released at the site of action. Thiol (sulfhydryl) containing molecules may be such a carrier. Notably, pegylation involves the addition of extra surface thiols on Hb (and albumin) to provide additional attachment sites for PEG. Since statistically not all added thiols react with PEG, there should be some unreacted molecules available for transporting NO. This mechanism also overcomes the problem of thiol-mediated NO transport by RBCs, which does not explain why the liberated NO is not immediately recaptured by Hb, given the diffusion barriers that exist in the RBCs prior the NO molecule being able to exit into the plasma. Finally, blood is a general transporter of gasses, a process that depends in part on the reaction with carrier molecules and in part on the solubility of the gases in plasma. Solubility is generally insufficient for carrying large amounts of gas as in the case of oxygen, however most other biological active gasses like NO, carbon monoxide (CO), and volatile anesthetics are effective in quantities that can be accommodate by solubility. Perflurocarbons (PFCs) which endow blood with gas solubility that is about twice that of plasma can be used effectively to increase gas solubility of blood, as well as act as carrier with which to introduce and distribute gasses into the circulation. Cabrales et al.11 provide new data supporting this concept and show how NO and CO can be introduced in a precise manner into the circulation. Furthermore, beyond being transported, these gases can also be temporarily stored in the PFC, which also acts as a reservoir for the gas, providing for a more uniform and predictable distribution as evidence by the apparent ability of PFCs to stabilize the effect of volatile anesthetics. A concept that emerges from this collection of papers is that there is no apparent evolutionary adaptation to the correction of exsanguination with a blood transfusion. Furthermore, blood transfusions present an inherent asymmetry: they are effective in reestablishing systemic conditions, primarily blood pressure and flow, however this is not necessarily reflected in the microcirculation, the critical system in which blood exerts its functions. Thus, the lack of a specific adaptation to blood transfusions, and the possibility of a microscopic asymmetrical response to blood restitution to correct for blood losses suggests that a blood substitute can be devised that is better than blood for the purpose of resuscitating an organism. Furthermore, since effective restoration of circulating volume is necessary, an effective blood substitute must be an effective plasma expander and restore microvascular function. It is not obvious that an optimal plasma expander has already been devised; and blood is probably not optimal in this context. Moreover, the design of a blood substitute that has the properties of native blood in the circulation may be unattainable, particularly because it is not possible to reproduce the biomechanical characteristics of blood which cause the microcirculation to be functional. Nevertheless, this can be achieved by recognizing that a critical property of a blood substitute is that of maintaining the functionality of the microcirculation, which is significantly dependent on an adequate supply of NO as well as oxygen. Both these gases can be transported by Hb, and current developments suggest that this potent biochemical can be controlled via the formation of PEG-Hb with the result that a product better than blood is theoretically possible and in the process of becoming available. All clinicians confronted with the need for transfusion of homologous blood express their hope to receive a safe and reliable alternative to red blood cells in order to ensure oxygen transport to the tissues. However, even though research on blood substitutes (or, better, red cell substitutes) started more than 100 years ago, until today none of the heavily investigated compounds based on hemoglobin or fluorocarbons has been released in Europe or the United States for routine clinical application. It would therefore appear that the problems, particularly with hemoglobin-based oxygen carriers (HBOCs), have been seriously underestimated. Fortunately enough, major advances have recently been made in terms of the pathophysiology of oxygen transport to the tissues under conditions of volume loss and hemodilution resulting from fluid resuscitation. One of the few laboratories contributing essential innovative ideas to the field of blood replacement and hemodilution as backbone of all alternatives to transfusion of donor blood and red blood cells is the microhemodynamic laboratory of Marcos Intaglietta at the University of California, San Diego (UCSD). Marcos Intaglietta is distinguished professor of bioengineering at UCSD and for many years he has devoted his efforts and the efforts of his research team to understanding the elementary basics of oxygen supply to normal and pathologically altered tissues. When planning this special issue of TATM, the editor could not identify any other scientist than Marcos Intaglietta to organize an up-to-date collection of papers on the different aspects of HBOCs and fluorocarbons with the aim to describe not only their effects, but also their side effects. It should be noted that their desirable effects can clearly be delineated, while their toxicities and potential side effects have so far prevented the release for clinical use of all of the various compounds in development. This issue shall provide the readers of TATM with the current state of the art. My very sincere thanks go to our guest editor Marcos Intaglietta for his dedication not only to the field of alternatives to blood and red cells, but also to our journal TATM.
No takes yet. Share an insight, caveat, or question.
Marcos Intaglietta (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: